Pfizer Reaffirms FY23 Guidance Provided In October Of Revenues Of $58B-$61B (Consensus Of $59.82B) And Adjusted EPS Of $1.45-$1.65 (Consensus Of $1.59)
Portfolio Pulse from Benzinga Newsdesk
Pfizer has reaffirmed its FY23 guidance, which was provided in October, of revenues between $58B-$61B and an adjusted EPS of $1.45-$1.65. The consensus estimates were $59.82B for revenues and $1.59 for EPS.
October 31, 2023 | 10:53 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pfizer's reaffirmation of its FY23 guidance aligns with consensus estimates, indicating stability in the company's financial outlook.
Pfizer's reaffirmation of its FY23 guidance, which is in line with consensus estimates, suggests that the company's financial outlook is stable. This could maintain investor confidence and keep the stock price steady in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100